CheckMate649 5-Year Follow-Up, Study Design, and Efficacy Results
Panelists discuss how the CheckMate649 study was a randomized trial that compared nivolumab plus FOLFOX (leucovorin, fluorouracil, oxaliplatin) chemotherapy with chemotherapy alone for treating advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. The study results found that nivolumab plus chemotherapy improved overall survival and progression-free survival compared with chemotherapy alone.
Recent Videos
Related Content
FDA Approves Pembrolizumab/Chemo in First-Line Gastric/GEJ Adenocarcinoma
March 19th 2025Article
Data from the phase 3 KEYNOTE-811 trial supported the FDA approval of this pembrolizumab combination in locally advanced unresectable or metastatic, PD-L1–positive, HER2-positive gastric or GEJ adenocarcinoma.
